Evommune (EVMN) Preferred Stock Liabilities (2024 - 2025)
Evommune (EVMN) posted quarterly Preferred Stock Liabilities of $257.0 million for Q3 2025, up 72.05% year-over-year from $149.4 million in Q3 2024, and up 34.01% quarter-over-quarter from $191.8 million in Q1 2025.
Powered by 
Analysis
Evommune (EVMN) Preferred Stock Liabilities (2024 - 2025) Analysis & Trends
Evommune (EVMN) has reported Preferred Stock Liabilities for 2 consecutive years, with $257.0 million the latest figure, recorded in Q3 2025.
- In Q3 2025, Preferred Stock Liabilities rose 72.05% year-over-year to $257.0 million; the TTM figure through Sep 2025 stood at $257.0 million (up 72.05% YoY), while the FY2024 annual figure was $191.8 million, changed N/A from the prior year.
- Preferred Stock Liabilities climbed to $257.0 million in Q3 2025 per EVMN's latest filing, from $191.8 million in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $257.0 million in Q3 2025 and bottomed at $149.4 million in Q3 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.78 Bn | 130.92 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.50 Bn | 77.51 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | - |
| 6 | BeOne Medicines | 40.04 Bn | 34.94 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | - |
| 9 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | - |
| 10 | Evommune | 445.37 Mn | 244.58 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2025 | 257.00 Mn |
| Jun 30, 2025 | 257.00 Mn |
| Mar 31, 2025 | 191.78 Mn |
| Dec 31, 2024 | 191.78 Mn |
| Sep 30, 2024 | 149.37 Mn |